Articles Written by:    JACOB GOLDSTEIN     

Pfizer Cleans Out Cabinets, Names Ex-General Mills CEO to Board

WSJ’s blog on health and the business of health. Pfizer is rummaging through the cabinets of its R&D unit, selling off experimental drugs that don’t fit with the company’s recent focus on fewer diseases. The plan is to sell to other companies about 1 ...

From JACOB GOLDSTEIN, Wall Street Journal,  14 Jan 2009
Related Topics: Pfizer Inc.,  General Mills, Inc.,  Wall Street Journal

The Next Step in Cancer Drugs: Who Should NOT Get Them

It may seem odd that a group of cancer docs is recommending against a popular treatment for many patients. But figuring out which patients are unlikely to benefit from cancer drugs — which are not only very expensive but can also be toxic — is a high ...

From JACOB GOLDSTEIN, Wall Street Journal,  14 Jan 2009
Related Topics: Amgen Inc.,  Bristol-Myers Squibb,  Food and Drug Administration

As States Cut Health Coverage for Poor, Feds Look to Do More

WSJ’s blog on health and the business of health. There are two big themes in health coverage for the poor in this country right now, and they’re moving in opposite directions. Theme 1: Strapped states are slashing their budgets for Medicaid — among ...

From JACOB GOLDSTEIN, Wall Street Journal,  14 Jan 2009
Related Topics: Barack Obama,  U.S. Democratic Party,  U.S. House of Representatives,  U.S. Senate,  U.S. Congress

What Kinds of Docs Are in Demand for Locum Tenens Jobs?

WSJ’s blog on health and the business of health. As the business of general surgery gets tougher, many surgeons are switching from traditional practices to locum tenens, temporary jobs where hospitals pay a day rate for general surgeons to come in ...

From JACOB GOLDSTEIN, Wall Street Journal,  13 Jan 2009
Related Topics: Wall Street Journal

Sleep Well to Fight Colds Better

Once again, science supports what you grandmother told you: A good night’s sleep helps your body fight a cold. People who averaged fewer than seven hours of sleep per night in the weeks before being exposed to the cold virus were nearly three times as ...

From JACOB GOLDSTEIN, Wall Street Journal,  12 Jan 2009

FDA Gives Light Scrutiny to Investigators’ Financial Ties

The IG’s office reviewed the paperwork for studies tied to the 118 marketing applications approved by FDA in FY ‘07. They found that 42% of approved applications were missing financial information, and only 1% of investigators disclosed financial ties. ...

From JACOB GOLDSTEIN, Wall Street Journal,  12 Jan 2009
Related Topics: Food and Drug Administration,  General Electric,  Eric Holder

As U.S. Economy Sheds Millions of Jobs, Health Care Adds Workers

WSJ’s blog on health and the business of health. The economy is crumbling and business are cutting jobs in almost every sector across the country. But health care is hiring. As the number of employees on nonfarm payrolls fell by more than two ...

From JACOB GOLDSTEIN, Wall Street Journal,  12 Jan 2009
Related Topics: Merck & Company, Inc.,  Wall Street Journal

Abbott Bets Another $2.8 Billion on Medical Devices

WSJ’s blog on health and the business of health. Abbott Labs is buying Advanced Medical Optics in a deal worth $2.8 billion. It’s Abbott’s latest push into medical devices — a diversification push that looking rather clever. Advanced Medical Optics, ...

From JACOB GOLDSTEIN, Wall Street Journal,  12 Jan 2009
Related Topics: Advanced Medical Optics, Inc.,  Barack Obama,  Wall Street Journal

Frank Torti, Science Guy, Named Acting FDA Commissioner

WSJ’s blog on health and the business of health. The new guy’s going run the FDA, at least for the time being. In this case that’s Frank Torti, an academic cancer researcher who joined the FDA just last year to take the newly created title of Chief ...

From JACOB GOLDSTEIN, Wall Street Journal,  12 Jan 2009
Related Topics: Food and Drug Administration,  Barack Obama,  Julie Gerberding,  Robert Wood Johnson,  Department of Health

Sabril: An Epilepsy Drug’s 15-Year FDA Odyssey

WSJ’s blog on health and the business of health. It was the mid-90s when the epilepsy drug Sabril first came before the FDA, and it’s not done yet. The latest twist came this week, when an FDA advisory committee voted unanimously to recommend ...

From JACOB GOLDSTEIN, Wall Street Journal,  9 Jan 2009
Related Topics: Food and Drug Administration,  Sanofi-Aventis,  Wall Street Journal

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry

Enter a url from sourcewatch.org or wikipedia.org:


recommend removal

close